Company / Current Liabilities
Arcus Biosciences, Inc. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$231.0M
FY2025
5-year range
$166.0M / $231.0M
FY2021-FY2025
Trend
+2.2%
vs FY2024
Sector context
#56 of 213
Health Care
What the data says
At $231M, Arcus Biosciences, Inc.'s current liabilities ranks #158 of 213 in the Health Care sector. Increased from $184M to $231M over the past 2 years.
Based on SEC 10-K filings.
$231M in FY2025 with a 5-year CAGR of +13.7%.
Increased from $184M to $231M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +6.2%
- 5-Year CAGR
- +13.7%
- 10-Year CAGR
- -
Sector benchmark
#158 of 213 in Health CareTop 74% of 213This company $231.0M Sector average $1.6B
▼
-85.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.7%, indicating consistent growth.
- In FY2025, current liabilities increased 2.2% year-over-year.
- Ranks #56 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $231.0M | +2.2% |
| FY2024 | $226.0M | +22.8% |
| FY2023 | $184.0M | -4.7% |
| FY2022 | $193.0M | +16.3% |
| FY2021 | $166.0M | +36.4% |
| FY2020 | $121.7M | +435.8% |
| FY2019 | $22.7M | +34.1% |
| FY2018 | $16.9M | +33.1% |
| FY2017 | $12.7M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026